SCHEMBL23622964

SCHEMBL23622964

Nc1cnn(C2CCC3(CC2)CC3)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 1/20 0.36
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34
PIK3CB P42338 1/20 0.34
PI4KA P42356 1/20 0.34
PIK3CG P48736 1/20 0.34
PI4KB Q9UBF8 1/20 0.34
ACHE P22303 3/20 0.33
MPO P05164 2/20 0.32
RET P07949 1/20 0.32
MET P08581 1/20 0.31
ALK Q9UM73 1/20 0.31
BMPR1A P36894 1/20 0.31
ACVRL1 P37023 1/20 0.31
ACVR1 Q04771 1/20 0.31
AURKA O14965 1/20 0.31
CDK1 P06493 1/20 0.31
AURKB Q96GD4 1/20 0.31
DDB1 Q16531 1/20 0.30
CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30173403 0.85 KDM5A (0.35) KDM5APIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL173506 0.85
SCHEMBL28214771 0.84 KDM5A (0.38) KDM5APIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL17076859 0.84 GSK3B (0.38) KDM5APIK3CDPIK3CAPIK3CBPI4KA
Hydrochloric Acid SCHEMBL31507950 0.83 PIK3CD (0.41) KDM5APIK3CDPIK3CAPIK3CBPI4KA
Hydrochloric Acid SCHEMBL25243994 0.83 PIK3CD (0.41) KDM5APIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL1703023 0.81 ACHE (0.44) KDM5APIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL16764416 0.81 ACHE (0.47) KDM5APIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL22097906 0.80 KDM5A (0.33) KDM5APIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL30173410 0.80 ACHE (0.35) KDM5AACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 US disclosed
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 US disclosed
WO-2021138434-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2021-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 KDM5A 3733/4885PIK3CD 830/4885PIK3CA 678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.